Schizophrenia Clinical Trial Landscape
Data updated: May 20, 2026
936 clinical trials tracked since 2008
Schizophrenia is a chronic brain disorder that affects a person's ability to think, feel, and behave clearly. It is a complex and often debilitating condition impacting individuals worldwide. The clinical trial landscape for schizophrenia is active, with 933 trials registered since 2008, including 109 currently active trials that are recruiting, enrolling, or active but not recruiting. The distribution of these active trials across phases reveals a focus on Phase 2 (40 active trials) and Phase 3 (33 active trials), suggesting ongoing efforts to evaluate efficacy and safety. Phase 1 trials account for 23 active trials, while Phase 4 trials account for 22 active trials. Industry sponsorship is led by Neurocrine Biosciences and Luye Pharma Group Ltd., each with 6 active trials. Bristol-Myers Squibb follows with 4 active trials, while Otsuka Pharmaceutical Co., Ltd. has 3 active trials, and Otsuka Pharmaceutical Development & Commercialization, Inc. has 2 active trials.
111 active
/
936 total (since 2008)
23
Phase 1 Active
256 total
41
Phase 2 Active
294 total
34
Phase 3 Active
252 total
22
Phase 4 Active
201 total
Top Industry Sponsors
Sorted by active Active Done Failed
Neurocrine Biosciences 6 7 3
Luye Pharma Group Ltd. 5 8 0
Bristol-Myers Squibb 4 0 0
Otsuka Pharmaceutical Co., Ltd. 3 7 1
Otsuka Pharmaceutical Development & Commercialization, Inc. 2 55 9
+ 10 more sponsors — see full table below
Featured Phase 3 Trials
NCT06882785 RECRUITING
A Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Participants With Schizophrenia
Bristol-Myers Squibb n=250
NCT07424404 RECRUITING
A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Autism-Related Irritability in Adolescents, Respectively
Karuna Therapeutics, Inc., a Bristol Myers Squibb company n=400
NCT07288567 RECRUITING
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
Bristol-Myers Squibb n=166
NCT07363577 RECRUITING
Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia
LB Pharmaceuticals Inc. n=456
NCT05303064 RECRUITING
Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
Alkermes, Inc. n=220
+ 247 more Phase 3 trials — see full database below
Schizophrenia — Trials Started by Year (last 10 years)
2016 38
2017 41
2018 37
2019 47
2020 27
2021 42
2022 38
2023 28
2024 33
2025 40
2026 22
TheraRadar.com
Full Trial Database
Complete sponsor table, every trial across all phases, plus competitive analytics. Sortable, filterable, exportable for Pro users.
Top Sponsors (all-time)
Neurocrine Biosciences 16
Luye Pharma Group Ltd. 13
Bristol-Myers Squibb 4
Otsuka Pharmaceutical Co., Ltd. 11
Otsuka Pharmaceutical Development & Commercialization, Inc. 66
Alkermes, Inc. 19
Karuna Therapeutics, Inc., a Bristol Myers Squibb company 12
Vanda Pharmaceuticals 6
LB Pharmaceuticals Inc. 5
Vigonvita Life Sciences 2
Active Trials by Phase
Phase 1 23
Phase 2 41
Phase 3 34
Phase 4 22
Enrollment Size Distribution
1-50 323
51-200 322
201-500 183
501-1k 66
1k+ 8
All Industry Sponsors
Sorted by active Active Done Failed
Neurocrine Biosciences 6 7 3
Luye Pharma Group Ltd. 5 8 0
Bristol-Myers Squibb 4 0 0
Otsuka Pharmaceutical Co., Ltd. 3 7 1
Otsuka Pharmaceutical Development & Commercialization, Inc. 2 55 9
Alkermes, Inc. 2 17 0
Karuna Therapeutics, Inc., a Bristol Myers Squibb company 2 9 1
Vanda Pharmaceuticals 2 4 0
LB Pharmaceuticals Inc. 2 3 0
Vigonvita Life Sciences 2 0 0
MapLight Therapeutics 2 0 0
Qilu Pharmaceutical Co., Ltd. 2 0 0
Intra-Cellular Therapies, Inc. 1 8 0
AbbVie 1 5 3
Novartis 1 6 0
NCT06882785 RECRUITING
A Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Participants With Schizophrenia
Bristol-Myers Squibb n=250
NCT07084831 NOT YET RECRUITING
A Study Evaluating the Efficacy of Xanomeline/Trospium (XT) on Cognitive Impairment After 24 and 52 Weeks of Treatment in Adult Participants With Schizophrenia
European Group for Research In Schizophrenia n=171
NCT07424404 RECRUITING
A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Autism-Related Irritability in Adolescents, Respectively
Karuna Therapeutics, Inc., a Bristol Myers Squibb company n=400
NCT07288567 RECRUITING
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
Bristol-Myers Squibb n=166
NCT07369154 NOT YET RECRUITING
52-week Open Label Safety-Tolerability Study
LB Pharmaceuticals Inc. n=900
NCT07363577 RECRUITING
Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia
LB Pharmaceuticals Inc. n=456
NCT04987229 ENROLLING BY INVITATION
Long-term Safety Extension Study of OLZ/SAM in Pediatric Subjects
Alkermes, Inc. n=236
NCT05303064 RECRUITING
Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
Alkermes, Inc. n=220
NCT07565428 RECRUITING
Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications
Minerva Neurosciences n=380
NCT06894212 RECRUITING
A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia
Otsuka Pharmaceutical Development & Commercialization, Inc. n=522
NCT07114874 RECRUITING
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
Neurocrine Biosciences n=600
NCT07263022 NOT YET RECRUITING
Cognitive Strategies in Early Psychosis 2
University of Minnesota n=24
NCT07105098 RECRUITING
NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
Neurocrine Biosciences n=284
NCT07227818 RECRUITING
Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia
Neurocrine Biosciences n=560
NCT07184619 RECRUITING
Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia
Newron Pharmaceuticals SPA n=400
NCT07045142 RECRUITING
Metformin Alleviates Abnormal Glucose Metabolism Induced by Statins in Schizophrenia Patients
Central South University n=400
NCT05304767 RECRUITING
An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia
Karuna Therapeutics, Inc., a Bristol Myers Squibb company n=280
NCT06963034 RECRUITING
NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
Neurocrine Biosciences n=284
NCT05603104 RECRUITING
Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure
Dr. Inge Winter n=1,254
NCT07225712 RECRUITING
A Long-term Administration Trial of SEP-363856 in Patients With Schizophrenia
Otsuka Pharmaceutical Co., Ltd. n=100
NCT06961968 RECRUITING
Randomized Withdrawal Study in Patients With Schizophrenia
Vanda Pharmaceuticals n=400
NCT05838573 RECRUITING
Metformin Treatment on Cognitive Impairment of Schizophrenia
Central South University n=120
NCT03817502 RECRUITING
Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
Gedeon Richter Plc. n=330
NCT06191965 RECRUITING
MitoQ for Early-phase Schizophrenia-spectrum Disorder and Mitochondrial Dysfunction
Mclean Hospital n=100
NCT06229210 RECRUITING
Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
Intra-Cellular Therapies, Inc. n=500
NCT05325645 RECRUITING
Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With Acute Schizophrenia
Otsuka Pharmaceutical Co., Ltd. n=450
NCT06799559 NOT YET RECRUITING
Study on the Efficacy and Safety of QLM1016 in Schizophrenia
Qilu Pharmaceutical Co., Ltd. n=402
NCT05184335 RECRUITING
Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
Reviva Pharmaceuticals n=690
NCT05326347 ACTIVE NOT RECRUITING
A Long-term Administration Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With Schizophrenia
Otsuka Pharmaceutical Co., Ltd. n=190
NCT06649214 NOT YET RECRUITING
A Study of Olanzapine-Samidorphan Tablets in Adults With Schizophrenia
Qilu Pharmaceutical Co., Ltd. n=654
NCT06589817 NOT YET RECRUITING
A Double-Blind, Randomized Comparative Study of Carliprazine and Aripiprazole in Patients with Acute Schizophrenia
Chengdu Kanghong Pharmaceutical Group Co., Ltd. n=376
NCT06482554 RECRUITING
Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms.
Louisiana State University Health Sciences Center Shreveport n=80
NCT06351514 RECRUITING
An Open-Label, Single Arm Study of the Efficacy of Accelerated Intermittent Theta Burst Stimulation in Schizophrenia Patients With Persistent Negative Symptoms
Institute of Mental Health, Singapore n=40
NCT03094429 RECRUITING
An Adaptive Phase II/III, Two-Part, Double-Blind, Randomized, Placebo-controlled, Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBen®, as an Add-on Therapy With Clozapine, for Residual Symptoms of Refractory Schizophrenia in Adults
SyneuRx International (Taiwan) Corp n=287
NCT05145413 COMPLETED
A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia
Karuna Therapeutics, Inc., a Bristol Myers Squibb company n=396
NCT05211947 TERMINATED
A Study to Test Long-term Safety of Iclepertin in People With Schizophrenia Who Took Part in a Previous CONNEX Study
Boehringer Ingelheim n=1,356
NCT03485417 COMPLETED
Substance Misuse To Psychosis for Stimulants
The University of Hong Kong n=165
NCT05693935 COMPLETED
A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy and Safety of TV-44749 in Adults With Schizophrenia
Teva Branded Pharmaceutical Products R&D LLC n=675
NCT05110157 COMPLETED
Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment for Schizophrenia
Neurocrine Biosciences n=442
NCT04857983 COMPLETED
Memantine Augmentation of Targeted Cognitive Training in Schizophrenia
University of California, San Diego n=62
NCT04860830 COMPLETED
CONNEX-3: A Study to Test Whether Iclepertin Improves Learning and Memory in People With Schizophrenia
Boehringer Ingelheim n=609
NCT03238326 COMPLETED
Safety and Tolerability of Open-Label Flexible-dose Brexpiprazole as Maintenance Treatment in Adolescents With Schizophrenia
Otsuka Pharmaceutical Development & Commercialization, Inc. n=295
NCT01626885 COMPLETED
A Long-Term Study of MP-214 in Patients With Receiving Multiple Drugs Schizophrenia
Tanabe Pharma Corporation n=42
NCT01625000 COMPLETED
Safety and Efficacy of MP-214 in Patients With Schizophrenia
Tanabe Pharma Corporation n=512
NCT01625897 COMPLETED
A Long-Term Study of MP-214 in Patients With Chronic Phase or Elderly Schizophrenia
Tanabe Pharma Corporation n=125
NCT01626859 COMPLETED
A Pharmacokinetic Study of MP-214 in Patients With Schizophrenia
Tanabe Pharma Corporation n=38
NCT01626872 COMPLETED
Long-Term Study of MP-214 in Patients With Schizophrenia
Tanabe Pharma Corporation n=254
NCT04115319 COMPLETED
A Study of the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia.
Otsuka Pharmaceutical Development & Commercialization, Inc. n=305
NCT05919823 COMPLETED
A Study to Assess the Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Chinese Adult Subjects With DSM-5 Schizophrenia
Karuna Therapeutics, Inc., a Bristol Myers Squibb company n=202
NCT04846881 COMPLETED
Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-2)
Boehringer Ingelheim n=611
NCT05628103 COMPLETED
A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antipsychotic Medication
Otsuka Pharmaceutical Development & Commercialization, Inc. n=101
NCT05741528 COMPLETED
An Extension Study to a Clinical Study That Will Continue to Evaluate the Effectiveness and Safety of SEP-363856 in People With Schizophrenia That Switch to SEP-363856 From Their From Their Current Antipsychotic Medication
Otsuka Pharmaceutical Development & Commercialization, Inc. n=75
NCT04846868 COMPLETED
Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-1)
Boehringer Ingelheim n=620
NCT04578756 COMPLETED
Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder
AbbVie n=310
NCT05368558 TERMINATED
Study to Assess Adverse Events and Change in Disease Activity of Oral Cariprazine Capsules in Adult Participants With Schizophrenia
AbbVie n=34
NCT06067984 COMPLETED
An Extension Study of a Second Course of a Digital Therapeutic for the Treatment of Experiential Negative Symptoms of Schizophrenia
Click Therapeutics, Inc. n=73
NCT05838625 COMPLETED
Study of Two Digital Therapeutics for the Treatment of Experiential Negative Symptoms of Schizophrenia
Click Therapeutics, Inc. n=464
NCT02469155 COMPLETED
A Trial to Assess the Antipsychotic Efficacy of ITI-007 Over 6 Weeks of Treatment
Intra-Cellular Therapies, Inc. n=696
NCT02282761 COMPLETED
A Trial to Assess the Antipsychotic Efficacy of ITI-007
Intra-Cellular Therapies, Inc. n=450
NCT05658510 COMPLETED
Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III)
BioXcel Therapeutics Inc n=452
NCT04820309 COMPLETED
An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5)
Karuna Therapeutics, Inc., a Bristol Myers Squibb company n=566
NCT03121586 TERMINATED
Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia
ACADIA Pharmaceuticals Inc. n=995
NCT04531982 COMPLETED
Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia
ACADIA Pharmaceuticals Inc. n=454
NCT03345342 COMPLETED
A Study of Paliperidone Palmitate 6-Month Formulation
Janssen Research & Development, LLC n=841
NCT02431702 COMPLETED
A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform
Janssen Scientific Affairs, LLC n=337
NCT04072575 COMPLETED
A Study of Paliperidone Palmitate 6-Month Formulation
Janssen Research & Development, LLC n=178
NCT02713282 COMPLETED
A Study of Transition to the Paliperidone Palmitate 3-Month Formulation In Participants With Schizophrenia Previously Stabilized on the Paliperidone Palmitate 1-Month Formulation
Janssen-Cilag Ltd. n=306
NCT03874494 COMPLETED
Safety and Efficacy of Brexpiprazole in the Treatment of Schizophrenia
Otsuka Beijing Research Institute n=371
NCT03510325 COMPLETED
Sequential Multiple-Assignment Randomized Trials to Compare Antipsychotic Treatments(SMART-CAT)
Shanghai Mental Health Center n=762
NCT06878833 WITHDRAWN
A Study to Evaluate the Safety and Tolerability of Long-Acting Oral Risperidone (LYN-005) in Participants With Schizophrenia or Schizoaffective Disorder
Lyndra Inc.
NCT06572449 COMPLETED
Study to Assess Safety and Effectiveness of Slowly Increasing Dose and Food Effect of KarXT in Participants With Schizophrenia
Karuna Therapeutics, Inc., a Bristol Myers Squibb company n=173
NCT05359081 TERMINATED
A Clinical Trial to Evaluate the Long-term Safety and Tolerability of SEP-363856 in Patients With Schizophrenia in Japan
Sumitomo Pharma Co., Ltd. n=68
NCT04109950 TERMINATED
A Clinical Study to Evaluate the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia
Otsuka Pharmaceutical Development & Commercialization, Inc. n=463
NCT04738123 COMPLETED
A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-3)
Karuna Therapeutics, Inc., a Bristol Myers Squibb company n=256
NCT05654870 TERMINATED
Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment for Schizophrenia
Neurocrine Biosciences n=8
NCT04959032 COMPLETED
Lumateperone for the Prevention of Relapse in Patients With Schizophrenia
Intra-Cellular Therapies, Inc. n=228
NCT04659174 COMPLETED
An Extension Study to Assess Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-4)
Karuna Therapeutics, Inc., a Bristol Myers Squibb company n=152
NCT01051531 COMPLETED
A Safety, Tolerability, and Treatment Response Study of Paliperidone Palmitate Administered to Patients With Schizophrenia
Janssen Research & Development, LLC n=546
NCT05779241 COMPLETED
Study to Evaluate the Pharmacokinetics (PK) and Safety/Tolerability of Long-Acting Oral LYN-005
Lyndra Inc. n=83
NCT03437668 TERMINATED
Adjunctive Withania Somnifera (Ashwagandha) for Persistent Symptoms in People With Schizophrenia
Chengappa, K.N. Roy, MD n=47
NCT03201757 COMPLETED
Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831
Alkermes, Inc. n=523
NCT02685748 COMPLETED
Aspirin in Young Psychotic Patients
Clinic for Psychiatric Disorders, Dr Laza Lazarevic n=60
NCT02067975 COMPLETED
Tryptophan MRI in People With Schizophrenia and Healthy Controls
University of Maryland, Baltimore n=93
NCT04072354 COMPLETED
A Clinical Trial to Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
Otsuka Pharmaceutical Development & Commercialization, Inc. n=463
NCT04092686 COMPLETED
A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
Otsuka Pharmaceutical Development & Commercialization, Inc. n=464
NCT01098110 COMPLETED
6-week Trial of the Efficacy and Safety of Asenapine Compared to Placebo in Participants With an Acute Exacerbation of Schizophrenia (P06124)
Organon and Co n=532
NCT01617187 COMPLETED
A Study of the Efficacy and Safety of Asenapine in Participants With an Acute Exacerbation of Schizophrenia (P05688)
Organon and Co n=360
NCT05643170 TERMINATED
An Open-label Study to Assess the Long-term Safety, Tolerability, Effectiveness, and Durability of Effect of KarXT in Patients With DSM-5 Diagnosis of Schizophrenia
Karuna Therapeutics, Inc., a Bristol Myers Squibb company n=4
NCT01142596 COMPLETED
Long-term Extension Trial of Asenapine in Subjects With Schizophrenia (Study P06125)
Organon and Co n=201
NCT01244828 COMPLETED
Long-term Study of Asenapine in Participants With Residual Subtype, Receiving Multiple or/and High Dose Drugs, or Treatment Refractory Schizophrenia (P06238)
Organon and Co n=157
NCT03896945 TERMINATED
Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Negative Symptoms of Schizophrenia
Otsuka Pharmaceutical Development & Commercialization, Inc. n=136
NCT02261519 TERMINATED
Study to Evaluate Safety & Efficacy of NaBen® as Add-on Treatment for Schizophrenia in Adults
SyneuRx International (Taiwan) Corp n=280
NCT01190267 COMPLETED
Flexible Dose, Long-term Safety Study of Asenapine for the Treatment of Schizophrenia in Adolescents (P05897)
Organon and Co n=204
NCT01190254 COMPLETED
Fixed Dose Efficacy and Safety Study of Asenapine for the Treatment of Schizophrenia in Adolescents (P05896)
Organon and Co n=306
NCT01908192 TERMINATED
Adaptive Phase II Study to Evaluate the Safety & Efficacy of NaBen®
SyneuRx International (Taiwan) Corp n=60
NCT01573637 COMPLETED
Raloxifene as an Adjuvant Treatment of the Negative Symptoms of Schizophrenia in Post-menopausal Women
Fundació Sant Joan de Déu n=78
NCT04825860 TERMINATED
A Clinical Trial to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic People With Schizophrenia, Followed by an Open-label Extension Phase
Sumitomo Pharma Co., Ltd. n=83
NCT03198078 COMPLETED
Trial to Evaluate the Short-term Safety & Efficacy of Brexpiprazole Monotherapy in the Treatment of Adolescents With Schizophrenia
Otsuka Pharmaceutical Development & Commercialization, Inc. n=316
NCT04659161 COMPLETED
A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-2)
Karuna Therapeutics, Inc., a Bristol Myers Squibb company n=252
NCT01291511 COMPLETED
Relapse Prevention Study in Patients With Schizophrenia
Vanda Pharmaceuticals n=635
NCT04268303 COMPLETED
Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia
BioXcel Therapeutics Inc n=380
NCT03397134 COMPLETED
Study to Evaluate Efficacy and Safety of Roluperidone (MIN-101) in Adult Patients With Negative Symptoms of Schizophrenia
Minerva Neurosciences n=515
NCT03503318 COMPLETED
Study to Evaluate TV-46000 as Maintenance Treatment in Adult and Adolescent Participants With Schizophrenia
Teva Branded Pharmaceutical Products R&D, Inc. n=544
NCT03465787 COMPLETED
A 6-week Study to Evaluate the Efficacy and Safety of Lurasidone HCL in Acutely Psychotic Patients With Schizophrenia
Bukwang Pharmaceutical n=210
NCT03187769 COMPLETED
Study to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who Have Been Recently Diagnosed With Schizophrenia, Schizophreniform, or Bipolar I Disorder
Alkermes, Inc. n=426
NCT03893825 COMPLETED
A Study to Test if TV-46000 is Safe for Maintenance Treatment of Schizophrenia
Teva Branded Pharmaceutical Products R&D, Inc. n=336
NCT01307800 TERMINATED
A Study of LY2140023 in Patients With Schizophrenia
Denovo Biopharma LLC n=567
NCT01328093 TERMINATED
A Comparison Study of LY2140023 and Aripiprazole in Schizophrenia Patients
Denovo Biopharma LLC n=678
NCT03788759 COMPLETED
Alpha-lipoic Acid Adjunctive Therapy in Schizophrenia
Nucleo De Pesquisa E Desenvolvimento De Medicamentos Da Universidade Federal Do Ceara n=48
NCT03149107 TERMINATED
"Multimodal Prevention of Psychosis - Investigating Efficacy of N-Acetylcysteine and Psychotherapy in CHR-Patients"
University Hospital, Bonn n=48
NCT00711269 COMPLETED
Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia
Sumitomo Pharma Co., Ltd. n=460
NCT01614899 COMPLETED
A Phase III Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia
Sumitomo Pharma Co., Ltd. n=457
NCT02335658 COMPLETED
Long-term Study of DSP-5423P in Patients With Schizophrenia
Sumitomo Pharma Co., Ltd. n=200
NCT02287584 COMPLETED
Confirmatory Study of DSP-5423P in Patients With Schizophrenia
Sumitomo Pharma Co., Ltd. n=580
NCT01614912 COMPLETED
Long-term Extension Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia
Sumitomo Pharma Co., Ltd. n=284
NCT03593213 TERMINATED
Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in a Dose-Reduction Paradigm in the Prevention of Relapse in Participants With Schizophrenia
AbbVie n=587
NCT03870880 COMPLETED
Study to Evaluate the Efficacy and Safety of Risperidone ISM® in Patients With Acute Schizophrenia: Open Label Extension
Rovi Pharmaceuticals Laboratories n=215
NCT03160521 COMPLETED
Study to Evaluate the Efficacy and Safety of Risperidone in Situ Microparticle (ISM)® in Patients With Acute Schizophrenia
Rovi Pharmaceuticals Laboratories n=438
NCT04327843 COMPLETED
Reducing the Burden of Chronic Psychotic Disorders in Tanzania (CAPACITY)
Case Western Reserve University n=22
NCT03043820 COMPLETED
Raloxifene Augmentation in Patients With a Schizophrenia Spectrum Disorder
Iris Sommer n=110
NCT03892889 TERMINATED
A Trial in Adult Participants With Schizophrenia Treated Prospectively for 6-months With Abilify MyCite®
Otsuka Pharmaceutical Development & Commercialization, Inc. n=277
NCT03955549 COMPLETED
Insight Enhancement Program vs. Metacognitive Training for Psychosis in Patients With Schizophrenia: A Three-Armed Comparative Randomized Controlled Trial
Agiad Psychiatry Hospital n=99
NCT02873208 COMPLETED
A Phase 3, Long-term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia
Alkermes, Inc. n=266
NCT01760993 TERMINATED
Long-term Safety of SPD489 When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia
Shire n=2
NCT01738698 TERMINATED
Adjunctive SPD489 to Antipsychotic Medication in Clinically Stable Adults With Persistent Predominant Negative Symptoms of Schizophrenia
Shire n=4
NCT01760889 TERMINATED
SPD489 Low Dose and High Dose Ranges When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia
Shire n=1
NCT01234298 WITHDRAWN
SPD489 as Adjunctive Treatment in Adults With Negative Symptoms of Schizophrenia
Shire
NCT00723606 COMPLETED
A Randomized, Open-Label, Multi-Center Study To Evaluate The Efficacy And Safety Of Intramuscular Ziprasidone In Patients With Agitation
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. n=376
NCT02983188 COMPLETED
Berberine as Adjuvant Treatment for Schizophrenia Patients
The University of Hong Kong n=113
NCT03172871 COMPLETED
Aripiprazole IM Depot in the Acute Treatment of Adults With Schizophrenia
Otsuka Beijing Research Institute n=436
NCT02892422 COMPLETED
Flexible-dose, Long-term Safety Study of Lu AF35700 in Adult Patients With Schizophrenia
H. Lundbeck A/S n=528
NCT02876900 COMPLETED
Study to Assess Efficacy and Safety of HP3070 in Subjects Diagnosed With Schizophrenia.
Noven Pharmaceuticals, Inc. n=617
NCT01999309 COMPLETED
Simvastatin Addition for Patients With Recent-onset Schizophrenia
Iris Sommer n=121
NCT01121042 COMPLETED
Double Blind, Placebo-Controlled, Randomised Investigation of Ondansetron in Schizophrenia
Bayside Health n=85
NCT03345979 COMPLETED
A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia
Alkermes, Inc. n=200
NCT02970292 COMPLETED
Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia (ENHANCE-1)
ACADIA Pharmaceuticals Inc. n=396
NCT03848234 COMPLETED
Estradiol Patch as add-on to Antipsychotics in Patients With Schizophrenia, Schizoaffective or Schizophreniform Disorder
Tangent Data n=209
NCT02773576 COMPLETED
Safety and Tolerability of Risperidone Implants
Braeburn Pharmaceuticals n=140
NCT02694328 COMPLETED
A Study of ALKS 3831 in Adults With Schizophrenia (The ENLIGHTEN-2 Study)
Alkermes, Inc. n=561
NCT03230864 TERMINATED
Efficacy of Lu AF35700 in Patients With Early-in-disease or Late-in-disease Treatment-resistant Schizophrenia
H. Lundbeck A/S n=119
NCT01129882 COMPLETED
An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Participants With Schizophrenia
Otsuka Pharmaceutical Development & Commercialization, Inc. n=709
NCT01456897 COMPLETED
A Long-term Trial of OPC-34712 in Patients With Schizophrenia
Otsuka Pharmaceutical Co., Ltd. n=282
NCT02717195 COMPLETED
Effect of Lu AF35700 in Patients With Treatment-resistant Schizophrenia
H. Lundbeck A/S n=1,098
NCT02002832 COMPLETED
A Clinical Trial of Lurasidone in Treatment of Schizophrenia
Sumitomo Pharma (Suzhou) Co., Ltd. n=388
NCT01451164 COMPLETED
A Dose-finding Trial of OPC-34712 in Patients With Schizophrenia
Otsuka Pharmaceutical Co., Ltd. n=459
NCT02669758 COMPLETED
A Long-Term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia
Alkermes, Inc. n=281
NCT01104792 COMPLETED
Long-term Study of Cariprazine in Patients With Schizophrenia
Forest Laboratories n=752
NCT02535676 COMPLETED
Schizophrenia TreAtment With electRic Transcranial Stimulation
University of Sao Paulo n=100
NCT03915938 COMPLETED
Ketamine's Effect Changes the Cortical Electrophysiological Activity Related to Semantic Affective Dimension of Pain
Hospital de Clinicas de Porto Alegre n=24
NCT01566162 COMPLETED
A Twelve Week, Open Label Extension Study in Patients With Schizophrenia
Sumitomo Pharma America, Inc. n=191
NCT01469039 COMPLETED
A Study to Evaluate the Efficacy and Safety of ALKS 9072 (Also Known as Aripiprazole Lauroxil, ALKS 9070, or ARISTADA) in Subjects With Schizophrenia
Alkermes, Inc. n=623
NCT01516424 COMPLETED
Efficiency Study to Investigate Blonanserin in Treatment of Schizophrenia When Compared With Risperidone
Sumitomo Pharma (Suzhou) Co., Ltd. n=267
NCT02194933 COMPLETED
Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Schizophrenia With Impulsivity
Otsuka Pharmaceutical Development & Commercialization, Inc. n=38
NCT01104766 COMPLETED
Safety and Efficacy of Cariprazine in Patients With Schizophrenia
Forest Laboratories n=617
NCT02109562 COMPLETED
Randomized, Double-blind, Placebo Controlled, Multi-center and Tolerability of RBP-7000 in Schizophrenia Patients
Indivior Inc. n=354
NCT02203838 COMPLETED
Long Term Study of RBP 7000 in the Treatment of Subjects With Schizophrenia
Indivior Inc. n=500
NCT01626456 COMPLETED
A Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)
Alkermes, Inc. n=478
NCT01412060 COMPLETED
A Study of Cariprazine in the Prevention of Relapse of Symptoms in Participants With Schizophrenia
Forest Laboratories n=765
NCT02634346 COMPLETED
A Study of ALKS 3831 in Adults With Acute Exacerbation of Schizophrenia (the ENLIGHTEN-1 Study)
Alkermes, Inc. n=403
NCT02374567 TERMINATED
Pharmacovigilance in Gerontopsychiatric Patients
Hannover Medical School n=407
NCT02308956 COMPLETED
Task Sharing for the Care of Severe Mental Disorders in a Low-income Country
University of Cape Town n=324
NCT01895452 COMPLETED
An Extension of a Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)
Alkermes, Inc. n=291
NCT00628589 COMPLETED
Staccato Loxapine in Agitated Patients With Schizophrenia
Alexza Pharmaceuticals, Inc. n=344
NCT01942148 COMPLETED
A Long-term, Extended Treatment Study of Aripiprazole in Pediatric Patients With Schizophrenia
Otsuka Pharmaceutical Co., Ltd. n=68
NCT01942161 COMPLETED
A Short Treatment Study of Aripiprazole in Pediatric Patients With Schizophrenia
Otsuka Pharmaceutical Co., Ltd. n=106
NCT01192867 COMPLETED
A Study of RO4917838 in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310)
Hoffmann-La Roche n=629
NCT01397786 COMPLETED
Safety and Tolerability Study of Oral OPC-34712 as Maintenance Treatment in Adults With Schizophrenia
Otsuka Pharmaceutical Development & Commercialization, Inc. n=1,044
NCT01911429 COMPLETED
Pediatric Schizophrenia Efficacy and Safety Study
Sumitomo Pharma America, Inc. n=327
NCT01173874 COMPLETED
Efficacy of Cognitive Remediation in Patients With Schizophrenia or Schizoaffective Disorder Stabilized on Lurasidone
New York State Psychiatric Institute n=120
NCT01795547 COMPLETED
Aripiprazole Once-monthly Versus Paliperidone Palmitate in Adult Patients With Schizophrenia
H. Lundbeck A/S n=295
NCT01192880 COMPLETED
A Study to Evaluate Efficacy and Safety of Bitopertin in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia
Hoffmann-La Roche n=625
NCT01668797 COMPLETED
Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults With Schizophrenia
Otsuka Pharmaceutical Development & Commercialization, Inc. n=524
NCT01295372 COMPLETED
Safety and Efficacy of Zicronapine in Patients With Schizophrenia
H. Lundbeck A/S n=160
NCT01235585 COMPLETED
A Study of RO4917838 (Bitopertin) in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (WN25306)
Hoffmann-La Roche n=597
NCT01235559 COMPLETED
A Study of RO4917838 (Bitopertin) in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (WN25305)
Hoffmann-La Roche n=604
NCT01192906 COMPLETED
A Study of RO4917838 (Bitopertin) in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (WN25309)
Hoffmann-La Roche n=624
NCT01585493 COMPLETED
CHANGE -it is About Life
Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital n=428
NCT02758067 WITHDRAWN
Comparison of the Effectiveness of Brexpiprazole With That of Risperidone
H. Lundbeck A/S
NCT01821378 COMPLETED
Lurasidone Low-Dose - High-Dose Study Study
Sumitomo Pharma America, Inc. n=412
NCT01391403 COMPLETED
Artemisinin With Risperidone for First-Episode and Drug-Naive Schizophrenia
Beijing HuiLongGuan Hospital n=88
NCT01529515 COMPLETED
A Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Patients With Schizophrenia
Janssen Research & Development, LLC n=509
NCT01716975 COMPLETED
Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
FORUM Pharmaceuticals Inc n=767
NCT01714661 COMPLETED
Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
FORUM Pharmaceuticals Inc n=753
NCT01714713 COMPLETED
A 26-Week Extension Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
FORUM Pharmaceuticals Inc n=830
NCT01515423 COMPLETED
Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia
Janssen Research & Development, LLC n=1,429
NCT02013622 COMPLETED
Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Early-Episode Schizophrenia
Otsuka Pharmaceutical Development & Commercialization, Inc. n=49
NCT00790192 COMPLETED
Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.
Sumitomo Pharma America, Inc. n=488
NCT01122927 TERMINATED
Safety and Tolerability of Aripiprazole in Adolescents With Schizophrenia or Children and Adolescents With Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features.
Otsuka Pharmaceutical Development & Commercialization, Inc. n=524
NCT01869660 COMPLETED
Shared Decision Making for Patients With First-admission Schizophrenia
Yokohama City University n=23
NCT02054702 COMPLETED
Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Acute Schizophrenia
Otsuka Pharmaceutical Development & Commercialization, Inc. n=97
NCT01393613 COMPLETED
Efficacy Study of OPC-34712 in Adults With Acute Schizophrenia
Otsuka Pharmaceutical Development & Commercialization, Inc. n=674
NCT01396421 COMPLETED
Study of the Effectiveness of Three Different Doses of OPC-34712 in the Treatment of Adults With Acute Schizophrenia
Otsuka Pharmaceutical Development & Commercialization, Inc. n=636
NCT00960375 COMPLETED
Smoking Cessation for Veterans With Severe and Persistent Mental Illness
US Department of Veterans Affairs n=179
NCT01794429 COMPLETED
Treatment of Antipsychotic-associated Obesity With a GLP-1 Analogue
Bjorn H. Ebdrup n=45
NCT00641745 COMPLETED
Lurasidone HCl - A Long Term Safety Phase 3 Study of Patients With Clinically Stable Schizophrenia
Sumitomo Pharma America, Inc. n=629
NCT01143090 COMPLETED
A Study of Subjects Switched to Lurasidone for the Treatment of Schizophrenia or Schizoaffective Disorder
Sumitomo Pharma America, Inc. n=149
NCT00615433 COMPLETED
Lurasidone HCl A Phase 3 Study of Patients With Acute Schizophrenia
Sumitomo Pharma America, Inc. n=478
NCT00789698 COMPLETED
Lurasidone HCl - A Long Term Phase 3 Study of Patients With Chronic Schizophrenia
Sumitomo Pharma America, Inc. n=240
NCT02458924 COMPLETED
Niacin Skin Flush Response in Patients With Schizophrenia
Isfahan University of Medical Sciences n=100
NCT01235520 COMPLETED
A Study of RO4917838 in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (NN25307)
Hoffmann-La Roche n=595
NCT01617200 COMPLETED
Long-Term Safety Extension Trial of Asenapine in Schizophrenia Participants Who Completed Protocol P05688 (P05689)
Forest Laboratories n=105
NCT01432444 COMPLETED
Open-label Study to Compare Hospitalization Rates of Schizophrenic Patients Treated With Oral Antipsychotics Versus IM Depot Aripiprazole
Otsuka Pharmaceutical Development & Commercialization, Inc. n=493
NCT01149655 COMPLETED
Efficacy & Safety Study of Oral Aripiprazole in Adolescents With Schizophrenia
Otsuka Pharmaceutical Development & Commercialization, Inc. n=252
NCT01683058 COMPLETED
Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia
Otsuka Pharmaceutical Development & Commercialization, Inc. n=74
NCT01509053 TERMINATED
Open-label Study to Compare Hospitalization Rates of Schizophrenic Patients Treated With Oral Antipsychotics Versus IM Depot Aripiprazole
Otsuka Pharmaceutical Development & Commercialization, Inc. n=30
NCT01081769 COMPLETED
Prevention of Relapse With Injectable Paliperidone Palmitate Versus Oral Antipsychotics
Janssen-Cilag International NV n=769
NCT01663532 COMPLETED
Trial of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in the Acute Treatment of Adults With Schizophrenia
Otsuka Pharmaceutical Development & Commercialization, Inc. n=340
NCT00731549 COMPLETED
Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
Otsuka Pharmaceutical Development & Commercialization, Inc. n=1,081
NCT01662310 COMPLETED
An Efficacy Study of Paliperidone for the Prevention of Relapse in Participants With Schizophrenia
Janssen Research & Development, LLC n=201
NCT01448720 COMPLETED
Treatment of Patients With Recently Exacerbated Schizophrenia With Paliperidone Palmitate
Janssen-Cilag Farmaceutica Ltda. n=142
NCT01363349 TERMINATED
Phase IIb-III Study of BL-1020 Small Molecule for Schizophrenia
BioLineRx, Ltd. n=269
NCT01258920 COMPLETED
A Study of Paliperidone Palmitate in Japanese Patients With Schizophrenia
Janssen Pharmaceutical K.K. n=201
NCT00654706 COMPLETED
Efficacy Study Exploring the Effects on Cognition of Sertindole Versus Comparator in Patients With Schizophrenia
H. Lundbeck A/S n=264
NCT02142556 COMPLETED
The Efficacy and Safety of Quetiapine XR in Patients With Schizophrenia Switched From Other Antipsychotics
Tri-Service General Hospital n=61
NCT01281527 COMPLETED
Paliperidone Palmitate Flexible Dosing in Schizophrenia
Janssen-Cilag International NV n=1,044
NCT00857818 TERMINATED
Trial Comparing the Effects of Aripiprazole With Those of Standard of Care on Non-HDL Cholesterol in Patients With Schizophrenia or Bipolar I Disorder Who Have Metabolic Syndrome
Otsuka Pharmaceutical Development & Commercialization, Inc. n=64
NCT01979679 COMPLETED
A D2 Receptor Occupancy and fMRI Study in Schizophrenic Subjects Treated With Lurasidone
University of California, Irvine n=28
NCT00706654 COMPLETED
Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
Otsuka Pharmaceutical Development & Commercialization, Inc. n=937
NCT01541371 COMPLETED
A Study of Flexibly Dosed Paliperidone Extended Release Tablets in Participants With Schizophrenia
Xian-Janssen Pharmaceutical Ltd. n=405
NCT00705783 COMPLETED
Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
Otsuka Pharmaceutical Development & Commercialization, Inc. n=843
NCT00604279 COMPLETED
A Comparative Study of Paliperidone Palmitate and Risperidone Long Acting Injection (LAI) in Participants With Schizophrenia
Xian-Janssen Pharmaceutical Ltd. n=452
NCT01009047 COMPLETED
An Efficacy and Safety Study of Extended-Release (ER) Paliperidone in Adolescent Participants With Schizophrenia
Janssen Research & Development, LLC n=228
NCT01299389 COMPLETED
An Efficacy and Safety Study of Paliperidone Palmitate in Participants With Schizophrenia
Janssen Pharmaceutical K.K. n=323
NCT01143077 COMPLETED
A Study Evaluating Lurasidone for The Treatment of Schizophrenia or Schizoaffective Disorder in Subjects Switched From Other Antipsychotic Agents
Sumitomo Pharma America, Inc. n=244
NCT01129674 TERMINATED
A Long-Term, Open-Label, Study on Schizophrenia
Eli Lilly and Company n=1,210
NCT00535574 COMPLETED
Bexarotene Augmentation of Antipsychotic Treatment for Chronic Schizophrenia
Beersheva Mental Health Center n=90
NCT00713804 COMPLETED
Impact of Genetic Counseling for Individuals With Mental Illness
University of British Columbia n=120
NCT00640601 COMPLETED
Study Evaluating the Clinical Benefit of SEROQUEL XR in Subjects With Schizophrenia
AstraZeneca n=331
NCT00882518 COMPLETED
Efficacy and Safety of Quetiapine Fumarate in the Treatment of Schizophrenic Patients
AstraZeneca n=388
NCT00970281 COMPLETED
A Study of Olanzapine in Patients With Schizophrenia
Eli Lilly and Company n=91
NCT00714818 COMPLETED
Impact of Genetic Counseling for Female First Degree Relatives of Individuals With Mental Illness
University of British Columbia n=13
NCT00894842 COMPLETED
Study of a Neurocognition Enhancing Agent in Patients With Schizophrenia
National Research Foundation, Singapore n=120
NCT00585390 COMPLETED
Omega-3 Fatty Acid Deficiency Replacement in Early Schizophrenia
University of Cincinnati
NCT01015001 COMPLETED
A Pilot Double-blind Sham-controlled Trial of Repetitive Transcranial Magnetic Stimulation for Patients With Refractory Schizophrenia Treated With Clozapine
Hospital de Clinicas de Porto Alegre n=20
NCT00640510 COMPLETED
A Study Comparing Rapid Acting Intramuscular Olanzapine and Placebo in Agitated Patients With Schizophrenia
Eli Lilly and Company n=34
Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only